Quantcast
Channel: All News Releases
Viewing all articles
Browse latest Browse all 2464

HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis

$
0
0

HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients with metabolic dysfunction-associated...


Viewing all articles
Browse latest Browse all 2464

Trending Articles